A5072282271- Lung Cancer Treatments and Mutations
- Cancer Genomics and Diagnostics
- Lung Cancer Diagnosis and Treatment
- Cancer Immunotherapy and Biomarkers
- Brain Metastases and Treatment
- Colorectal Cancer Treatments and Studies
- Radiomics and Machine Learning in Medical Imaging
- Pancreatic and Hepatic Oncology Research
- Chemotherapy-induced cardiotoxicity and mitigation
- Genetic factors in colorectal cancer
- Prostate Cancer Treatment and Research
- Occupational and environmental lung diseases
- Lung Cancer Research Studies
- Molecular Biology Techniques and Applications
- Frailty in Older Adults
- Cancer Diagnosis and Treatment
- Cancer Treatment and Pharmacology
- Cancer therapeutics and mechanisms
- Chemotherapy-induced organ toxicity mitigation
- Indoor Air Quality and Microbial Exposure
- Hepatocellular Carcinoma Treatment and Prognosis
- Gastric Cancer Management and Outcomes
- Graphene and Nanomaterials Applications
- Digestive system and related health
- Inflammatory Biomarkers in Disease Prognosis
Royal Marsden Hospital
2019-2024
Royal Marsden NHS Foundation Trust
2017-2024
Genomic sequencing is necessary for first-line advanced non-small cell lung cancer (aNSCLC) treatment decision-making. Tissue next generation (NGS) standard but tissue quantity, quality, and time-to-results remains problematic. Here, we compare upfront cell-free-DNA (cfDNA) NGS clinical utility against routine testing in patients with aNSCLC.cfDNA-NGS was performed consecutive, newly identified aNSCLC between December 2019-October 2021 alongside genotyping. Variants were interpreted using...
Lorlatinib is a third generation ALK inhibitor with marked efficacy in NSCLC. CTCAE-defined weight gain and dyslipidaemia has been reported patients receiving lorlatinib registrational trials. Lipid-lowering agents may interact metabolism. We conducted single centre retrospective analysis of NSCLC lorlatinib. The primary objective was to quantify lipid profile changes accordance CTCAE v5.0. Extraction from electronic medical records undertaken by authors. Mean relative dose intensity (RDI)...
Durvalumab is the first approved adjuvant immunotherapy agent for patients with stage III NSCLC treated concurrent chemoradiotherapy and associated improved overall survival. In order to minimise number of hospital visits receiving durvalumab during COVID-19 pandemic we implemented 4-weekly (20 mg/kg) in place 2-weekly infusions at The Royal Marsden Hospital. We assessed potential impact safety a schedule durvalumab. carried out retrospective study 40 prior pandemic. Clinical documentation...
e14011 Background: 30-50% of NSCLC patients develop brain metastases (BM). Re-evaluation the role SRS is required with evolving understanding molecular subtypes and increasing intracranial efficacy systemic agents. Methods: We conducted a retrospective analysis receiving at our centre from 05/16-11/23. Primary objective was median overall survival (mOS months). Analysis performed on Prism 10.1.1. Multivariate using Cox Proportional Hazards Regression, age, gender, KPS, BM size, total volume...
Background: Genomic sequencing is necessary for first-line advanced non-small cell lung cancer (aNSCLC) treatment decision-making. Tissue next-generation-sequencing (NGS) standard but tissue quantity, quality, and time-to-results remains problematic. Here, we compare upfront cell-free-DNA (cfDNA) NGS clinical utility against routine testing in patients with aNSCLC. Methods: cfDNA-NGS was performed consecutive, newly-identified aNSCLC between December 2019-October 2021 alongside genotyping....